Ischemia-induced angiogenesis contributes to various neuronal and retinal diseases, and often results in neurodegeneration and visual impairment. Current treatments involve the use of anti-VEGF agents but are not successful in all cases. In this study we determined that miR30a-5p is another important mediator of retinal angiogenesis. Using a rodent model of ischemic retinopathy, we show that inhibiting miR-30a-5p reduces neovascularization and promotes tissue repair, through modulation of microglial and endothelial cell cross-talk. miR30a-5p inhibition results in increased expression of the death receptor Fas and CCL2, to decrease endothelial cell survival and promote microglial migration and phagocytic function in focal regions of ischemic injury. Our data suggest that miR-30a-5p inhibition accelerates tissue repair by enhancing FasL-Fas crosstalk between microglia and endothelial cells, to promote endothelial cell apoptosis and removal of dead endothelial cells. Finally, we found that miR-30a levels were increased in the vitreous of patients with proliferative diabetic retinopathy. Our study identifies a role for miR-30a in the pathogenesis of neovascular retinal disease by modulating microglial and endothelial cell function, and suggests it may be a therapeutic target to treat ischemia-mediated conditions.
VEGF may lead to hypoxia, exacerbate retinal ischemia (Lee, Kang, & Koh, 2017; Toy, Schachar, Tan, & Moshfeghi, 2016) and lead to degeneration of retinal neurons and retinal pigment epithelium (RPE) (Ashraf et al., 2016; Gemenetzi et al., 2017; Keir et al., 2017) . Thus, there is a large unmet medical need to develop new, targeted therapies that will either improve efficacy or reduce off-target effects when used in combination with anti-VEGF drugs. microRNAs (miRs) have been the focus of widespread interest (Rupaimoole & Slack, 2017) . These are 22-25 base pair, noncoding RNA molecules that have emerged as potent regulators of physiological processes such as angiogenesis and tissue repair (Anand et al., 2010; Gallach, Calabuig-Fariñas, Jantus-Lewintre, & Camps, 2014; Westenskow et al., 2013) . Through sequence complementarity of their "seed sequence," that is, nucleotides 2-7/8, miRs bind to target mRNAs to repress protein expression through one of three mechanisms: degradation of target mRNA, destabilization of target mRNA, or inhibition of translation. One novel aspect of miRs, is that they can target several mRNAs within the same pathway or biological process, and, thus, potently regulate biological processes (Rupaimoole & Slack, 2017) , making them attractive candidates as therapeutics. For example, in this study, we observe that miR-30a inhibition results in increased expression of two of its targets, Fas and CCL2. Specific miRs have been identified that play key roles in angiogenesis, ischemia, glial responses, and microglial activation (Hutchison et al., 2013;  Landskroner-Eiger, Moneke, & Sessa, 2013; Ponomarev, Veremeyko, & Weiner, 2013; Wang, Yang, & Tzeng, 2015; Zhang, Dong, Li, Hong, & Wei, 2012) . Recent evidence suggests that miRNAs, contained within microvesicles, can modulate nervous tissue responses to ischemia and glial cell-to-cell communication (Blandford, Galloway, & Moore, 2018) , as is the case in oxygen-induced retinopathy (OIR) (Dellett et al., 2017) . Analysis of these vesicles showed that miR-30a-5p (miR-30a) was one of the most enriched miRs. miR-30a is particularly interesting as increased expression is associated with ischemia and vascular comorbidities such as obesity, diabetes, stroke, and subarachnoid hemorrhage (Carreras-Badosa et al., 2015; Long et al., 2013; Muller et al., 2015; Nielsen et al., 2012) . Finally, miR-30a is highly expressed in proliferating endothelial cells in vitro (Anand et al., 2010) , is enriched in microglia (Butovsky et al., 2014) , and has recently been shown to be one of the 10 most abundant miRNAs in the human retina (Karali et al., 2016) .
Microglia are of yolk-sac origin and the tissue resident macrophages of the brain and retina (Ginhoux & Prinz, 2015) . They are the first responders to CNS injury, including ischemia (Paques et al., 2010) . As the tissue resident macrophages of the retina, microglia perform many of the same functions as other macrophages (Murinello, Mullins, Lotery, Perry, & Teeling, 2014; Perry & Holmes, 2014) . It is known that these cells play a critical role in retinal angiogenesis both at key developmental time points and during disease progression (Biswas, Bachay, Chu, Hunter, & Brunken, 2017) . FasFas ligand (FasL) interactions have been documented as an important mechanism to curb abnormal angiogenesis following ischemia.
Specifically, interactions between Fas-expressing endothelial cells
and FasL-expressing microglia have been shown to promote endothelial cell apoptosis (Barreiro, Schadlu, Herndon, Kaplan, & Ferguson, 2003) . Microglial cells have also been implicated in retinal tissue repair following ischemic injury (Ritter et al., 2006) . A key function necessary for appropriate tissue repair is phagocytosis of cellular debris and extracellular matrix, clearing tissues to facilitate appropriate revascularization and repair (Fadok et al., 1998; Khanna et al., 2010; Swift, Burns, Gray, & DiPietro, 2001) . Thus, in addition to targeting endothelial cells, manipulating microglia behavior is an alternative strategy to prevent pathological angiogenesis and promote repair following injury Ritter et al., 2006; Rutar, Natoli, Chia, Valter, & Provis, 2015) . We have previously shown that supporting microglia survival is instrumental in promoting retinal tissue repair and healthy revascularization following ischemic retinal damage (Ritter et al., 2006) , but the mechanisms that regulate microglia function during ischemia remain incompletely understood. Certain miRNAs are known to modulate glial behavior (Amici, Dong, & Guerau-de-Arellano, 2017; Wang, Yang, et al., 2015; Zhang et al., 2012) , and miR-30a is highly enriched in microglia (Butovsky et al., 2014) , although its precise impact on these cells remains unknown. miR-30a is conserved in humans and mice, and regulating miR-30a in microglia could have broad utility for treating a number of ischemic neuropathies.
| METHODS

| Reagents and antibodies
Isolectin GS-IB 4 (IB4) labeled Alexa Fluor 647 (I32450) and 488 (I21411) and rat anti-mouse CD11b (MA5-16528) were purchased from Thermo Fisher Scientific. Rabbit anti-mouse/human PU.1 Violet 421 anti-human CD95 (Fas, 305, 623) , were obtained from BioLegend. PE and Brilliant Violet 421 anti-mouse CD95 (Fas, 561, 985 and 562,633) were obtained from BD Biosciences. LIVE/DEAD fixable near-IR dead cell stain (L34975) was obtained from Thermo Fisher Scientific. Recombinant human sFas Ligand (310-03H) and recombinant murine JE/MCP-1 (CCL2, 250-10) were obtained from PeproTech. mirVana miRNA inhibitors hsa-miR-30a-5p (4464084) and negative control #1 (4464076), were obtained from Thermo Fisher Scientific.
For cell culture transfections, hsa-miR-30a-5p (MIM0091) and nontargeting_1 (MIM9001) mimic and hsa-miR-30a-5p (INH0091) and nontargeting_1 (INH9001) inhibitors were obtained from Switchgear Genomics. In situ hybridization probes for hsa-miR-30a-5p (cat VM1-10240-01) and CCL2 (cat VB1-13201-01) were obtained from Affymetrix.
| Mice and animal experimental procedures
All animal protocols were approved by the IACUC committee at the Scripps Research Institute, La Jolla, California. All animals received food and water ad libitum. C57BL6 mice were obtained from The Scripps Research Institute animal facility. CCL2 flox and LysM-cre mice on a C57BL6 background were obtained from The Jackson Laboratory. OIR was induced as previously described (Smith et al., 1994) .
Briefly, postnatal day 7 (p7) pups and their mothers are exposed to an environment of 75% oxygen in a hyperoxia chamber (BioSpherix ProOx P110) for 5 days and returned to room air at p12. Under these conditions, retinal neovascularization (NV) occurs between P12 and P17. Intravitreal injections of anti-miR-30a and scramble-miR control (0.5 μl of a 100 μM solution) or recombinant murine CCL2 (0.5 μl of a 0-5,000 ng/ml) were performed at p12, immediately after returning the mice to normal room air. An in vivo phagocytosis assay was performed as previously described (Murinello et al., 2016) . Mice were euthanized by cervical dislocation at varying time points, as indicated in the results and figure legends. 
| Human vitreous collection
| Cells and cell culture
HUVECs (Thermo Fisher Scientific, C-003-5C) were cultured in M200
(Thermo Fisher Scientific, M-200-500) supplemented with LVES (Thermo Fisher Scientific, A14608-01). HUVECs were seeded at 1.3 × 10 4 cells/cm 2 24 hr before transfection. Cells were transfected with Lipofectamine RNAiMAX (Thermo Fisher Scientifc, 13, 778, 075) according to manufacturer's instructions, for 6 hr. After 6 hr, cells were incubated in complete media with or without 100 ng/ml of recombinant sFasL, as indicated in figure legends, for 15 hr until used for downstream applications.
| Proliferation assay
Proliferation was assessed by measuring incorporation of bromodeoxyuridine (BrdU) and cell cycle phase was determined by costaining with the total DNA stain, 7-AAD, using a flow cytometric kit from BD Biosciences (559619). 
| Immunofluorescence
Eyes were collected and fixed in 4% paraformaldehyde for 4 hr at 
| In situ hybridization
Eyes were fixed in 4% paraformaldehyde at 4 C for 20 hr, incubated in 30% sucrose at 4 C for 24 hr, embedded in OCT, and stored at −80 C. Samples were sectioned at 7 μm and melted onto Superfrost Plus Microscope Slides (Fisher Scientifc, . Slides were dried at room temperature for 1 hr and stored at −80 C. In situ hybridization was performed using the Affymetrix ViewRNA ISH Tissue Assay kit (QVT0050) according to manufacturer's instructions with an additional fixation in 4% paraformaldehyde at 4 C for 16 hours prior to step 1 and excluding heat pretreatment of slides.
Retinas were imaged usinf a Zeiss 710 Confocal microscope (Zeiss).
| RNA isolation and real-time PCR
Single retinas were collected in 500 μl of Triazol and RNA was isolated using a PureLink RNA mini kit (Thermo Fisher Scientific, 12,183,020) according to manufacturer's instructions. 125 ng of RNA were used for RT-qPCR using a high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific, 4, 368, 814) . qPCR was performed using Taqman universal master mix (Thermo Fisher Scientific, 4, 304, 437) and Taqman probes on a Quantstudio 5 (Thermo Fisher Scientific). For analysis of microRNA experiments, sRNAU6 was used as the reference gene; for mouse studies beta actin was used as the gene; for human studies GAPDH was used as the reference gene.
| Purification of microRNA from human vitreous
Purification of miR-30a-5p from human vitreous was performed using a TaqMan miRNA ABC Purification kit-Human Panel B (Thermo Fisher Scientific) following manufacturer's instructions.
| Flow cytometry analysis of mouse retinas
A postnatal neural dissociation kit (Miltenyi, 130-092-628) was used to prepare a single cell suspension from mouse retinas, and cells were stained as previously described (Murinello et al., 2016) . Stained cell suspensions were analyzed using a LSR-II flow cytometer (BD Biosciences). Fluorescence minus one (FMO) controls were used for each antibody. Analysis of acquired data was performed in FlowJo v10 (Flowjo, LLC).
| Protein analysis with mesoscale discovery system
Protein analysis was performed using Mesoscale Discovery Systems following manufacturer's instructions. Hundread micrograms of protein homogenate in 25 μl of T-Per buffer with 1× Halt protease inhibitor cocktail (Thermo Fisher Scientific, 78,429) were added to each well of a 96-well plate.
| Statistics
All statistical tests were performed in GraphPad Prism v6.07
(GraphPad Software, Inc). Data comparisons between two groups were performed using unpaired or paired two-tailed Student t-tests.
Data comparisons between multiple groups were performed with multiple t-test with Holmes-Sidak correction or one-way ANOVA with Bonferroni correction. Data comparison between two groups with more than one variable were performed with two-way ANOVA and Bonferroni correction. Tests used for each experiment are specified in the figure legends. Data are represented as mean AE SEM. A p value of p < .05 was considered significant.
| Study approvals
Human studies were approved by the institutional review committee of Tokyo Medical University Hospital. Informed consent for surgery and sampling was obtained according to the Declaration of Helsinki.
All animal studies have been approved by TSRI's IACUC review board.
3 | RESULTS
| miR-30a inhibition reduces NV and promotes retinal repair following ischemia
We confirmed that miR-30a functions as an angiomiR (a miR that promotes angiogenesis) through overexpression studies using HUVECs (Supporting Information Figure 1 ). Transfection of HUVECs with a miR-30a mimic led to increased cell proliferation (Supporting Information Figure 1A and B), modestly reduced apoptosis, and promoted tube formation (Supporting Information Figure 1C -F) . Using the OIR model we determined that miR-30a also promotes angiogenesis in vivo. We examined the spatial/temporal expression pattern of miR30a in OIR mice, and observed profound changes that positively and negatively correlated with the pathological (i.e., proliferative) and physiological (i.e., tissue repair) neovascular phases, respectively ( Figure 1a ). Using qPCR we determined that at p12 to p14 stages, when NV is occurring from the superficial and inner vessels (Connor et al., 2009 ), miR-30a levels spike, but they rapidly drop at the onset of the repair phase (p17; Figure 1b Fas levels increase and apoptosis of endothelial cells is promoted.
| miR-30a regulates retinal microglia migration
We hypothesized that while miR-30a does not regulate FasL in microglia, it does promote migration and this can increase FasL bioavailability, thereby influencing endothelial cell survival. To test this hypothesis, we performed loss-of-function analyses in OIR mice during neovascular stages. Distribution of microglia is uneven in ischemic inner retina in OIR mice due to vaso-obliteration and NV, but is normalized in eyes injected with miR-30a inhibitors (Figure 3a and b) .
These microglia likely migrated from the deeper regions of the inner retina (Figure 2b ) supported by flow cytometry analyses which revealed no significant differences in total number of microglia following injection of miR-30a inhibitors (Figure 3c ). Migration of microglia toward ischemic injury sites could potentiate interactions between FasL-expressing microglia and Fas-expressing endothelial cells, to promote endothelial cell apoptosis.
| miR-30a modulates CCL2 expression
CCL2 is a nonconserved target of miR-30a ( Figure 4A ) that promotes chemotaxis (Conductier, Blondeau, Guyon, Nahon, & Rovere, 2010) and is upregulated in several CNS disorders. Therefore, we investigated if miR-30a can modulate CCL2 in the retina. CCL2 mRNA expression showed an inverse expression pattern to that of miR-30a (Figure 4b and c-compare with Figure 1b) , during the time course of OIR, indicating miR-30a targets CCL2 in the retina. Moreover, inhibition of anti-miR-30a
resulted in increased levels of CCL2 mRNA (Figure 4d ) and protein Retinal miR-30a levels were quantified by qPCR in retinas from normoxic and OIR mice (n = 6-17 mice per group and representative of at least two independent experiments). Patho NV-Pathological NV, Phys NV-Physiological NV. Data are mean + SEM. p-values were calculated using two-way ANOVA with Bonferroni correction, *p = .0221, **p = .0049, ***p = .0005. (c) Immunofluorescent staining with isolectin B4 (IB4) was performed to detect blood vessels in OIR retinas at p17. Top panels shows representative images, bottom panels show neovascular areas pseudocolored in red and vaso-obliterated areas pseudocolored in yellow. (d and e) quantification of neovascular (d) and vaso-obliterated (e) areas (n = 15-16 mice per group, from four independent experiments). p-values were calculated using a two-tailed Student's t-test, **p = .0019, ***p < .0001. Data are mean + SEM. Scale bars-50 μM (Figure 4e ) in the retina. Finally, following miR-30a inhibition, CCL2 expression was predominantly in the inner, ischemic layers, consistent with the microglial migration patterns and miR30a expression patterns we observed (Figure 4f ) . Therefore, microglia migration may be regulated by miR-30a and CCL2 signaling during ischemia to regulate, at least in part, the neovascular and repair phases of OIR.
| CCL2 partially mediates the effects of miR-30a inhibition
To further identify the cellular source of CCL2, we sorted endothelial and microglial cells following intravitreal injection of miR-30a inhibitor. While both cell-types responded to miR-30a inhibition by upregulating CCL2 mRNA, microglial cells (average C T = 28.4) expressed higher levels of CCL2 than endothelial cells (average C T = 35.7; data not shown). To confirm the role of CCL2 as a mediator of the effects of miR-30a inhibition we used a Lysm-Cre to deplete CCL2 in microglia. As predicted, inhibiting miR-30a in LysM-cre CCL2 fl/fl (CCL2 KO) mice had no significant effect (Figure 5b,c) . The role of CCL2 in angiogenesis is controversial, but it is traditionally viewed as a proangiogenic factor (Cerri et al., 2016; Fernando, Natoli, Valter, Provis, & Rutar, 2016; Robbie et al., 2016) . Interestingly, we found that enhancing CCL2 levels in the retina by intravitreal injection of recombinant murine CCL2 (rmCCL2) resulted in a dose-dependent reduction in NV and vaso-obliteration (Figure 5d-f ) . These data suggest that CCL2
could act as an inhibitor of retinal angiogenesis, a previously unknown role for this chemokine. The percentage of endothelial cell death. n = 9 mice per group, from three independent experiments. Data are mean + SEM. p-value was calculated using a two-tailed Student's t-test, *p = .019
| miR-30a regulates microglial phagocytic function by targeting CCL2
We used transcriptomic and functional assays to determine that miR30a and CCL2 can enhance microglia phagocytic function in the retina. 
| DISCUSSION
Understanding the role of miRs in health and disease has been of interest to many researchers. As they can fine-tune biological processes by modulating expression of several genes in a particular pathway, they are being studied in various disease contexts (Christopher et al., 2016; Garden & Campbell, 2016) . In fact, modulators of specific miRs including miR-155, miR-29, miR-122, and miR-34a are being studied and tested in clinical trials (Rupaimoole & Slack, 2017) . In this study, we describe the role of miR-30a in modulating ischemic responses by focally controlling endothelial cell survival in precise temporal/spatial patterns. Inhibition of miR-30a not only reduced 
Endothelial cells of both the retinal and choroidal vasculatures express
Fas and their cell fate is regulated by interaction with FasL expressed by microglia or RPE, respectively (Barreiro et al., 2003; Kaplan et al., 1999) .
In particular, FasL-expressing macrophages can migrate to areas of tissue injury to promote endothelial cell apoptosis and thus reduce pathologic NV (Barreiro et al., 2003; Kelly, Ali Khan, Yin, Ferguson, & Apte, 2007 ).
Here we show that miR-30a inhibition can simultaneously promote Fas expression by endothelial cells and promote migration of FasL-expressing microglia towards the sites of ischemic injury. Thus, by promoting endothelial and microglial cell interactions, miR-30a inhibition can lead to increased endothelial cell death and, thus, directly decrease NV.
FIGURE 4 miR-30a inhibition leads to increased levels of CCL2. (a) CCL2 is a nonconserved target of miR-30a. (b and c) CCL2 expression in OIR retinas occurs in an opposite pattern to that of miR-30a. (b) CCL2 mRNA levels are increased during the repair phase, contrasting to those of miR30a (n = 4-8, from at least two independent experiments). Data are mean + SEM. p-values were calculated using two-way ANOVA with Bonferroni correction, *p = .012, ***p < .0001. (d and e) inhibition of miR-30a resulted in increased levels of CCL2 mRNA (d), measured by qPCR, and protein (e), measured by MSD (n = 4 retinas per group, from two to three independent experiments). Data are mean + SEM. p-values were calculated using two-way ANOVA with Bonferroni correction, *p < .05, **p < .001, ***p < .0001. (F) In situ hybridization showed that increased levels of CCL2 (red) following miR-30a injection are mostly observed in the superficial layers, consistent with microglial migratory patterns observed (n = 4 mice per group). Images are representative of two independent experiments. Scale bar −50 μm While they are known to perform a variety of functions that are essential for tissue homeostasis, their precise involvement and contribution to diseases of the CNS is still unresolved (Colonna & Butovsky, 2017; Perry & Holmes, 2014; Usui et al., 2015) . An overwhelming amount of literature supports that microglia contribute to pathological changes through secretion of proinflammatory cytokines leading to cytotoxicity (Chen & Xu, 2015; Madeira, Boia, Santos, Ambrosio, & Santiago, 2015; McVicar et al., 2015; Murinello et al., 2014; Perry & Holmes, 2014; Zhang et al., 2012) . However, few recent studies have
shown that in certain instances, microglia activation can be protective (Chuang et al., 2016; Holtman et al., 2017; Le, Wu, & Tang, 2016; White et al., 2017) . With regard to ischemic injury of the CNS, microglia depletion has been shown to induce more severe ischemic neuronal damage (Szalay et al., 2016) . These results are consistent with our previous findings that maintaining microglial numbers in the retina protects against ischemic damage in the OIR model (Ritter et al., 2006) . Moreover, a recent study by Biswas et al., has demonstrated that microglia activation and interaction with the mural basement membrane can promote physiologic angiogenesis, promoting retinal tissue repair (Biswas et al., 2017) . Here, we show that miR-30a inhibition leads to increased coverage of avascular areas by microglia and is associated with increased revascularization. It is possible that microglia are promoting revascularization through mechanisms described previously (Biswas et al., 2017) . Furthermore, we demonstrated that miR-30a inhibition results in increased phagocytic function by microglia. Phagocytosis of cellular debris is critical in ensuring the microenvironment is primed for appropriate revascularization and tissue repair (Bulow, 1978; Jin & Yamashita, 2016) . In response to miR-30a inhibition, microglia migrate to areas of tissue injury, where they may phagocytose dead or compromised endothelial cells, as well as extracellular matrix, to facilitate tissue repair. Based on cell morphology and flow cytometric analysis of cell-surface markers, our data indicate that the observed migrating CD11b + cells are mostly microglia. However, we cannot completely rule out the hypothesis that some bone-marrow derived cells may infiltrate the retina and contribute to the observed effects. Through its impact on these cells, miR30a inhibition may promote physiological NV, thus leading to a reduction in vaso-obliteration.
The work presented here shows that miR-30a inhibition has a profound effect on microglia and endothelial cells, thus suppressing and vaso-obliteration (c) (n = 4-6 mice per group, from two independent experiments). Data are mean + SEM. p-values were calculated using two-way ANOVA with Bonferroni correction, **p = .0035. (df ) injection of recombinant CCL2 is sufficient to reduce NV (d) and avascular areas (e) in OIR in a dose dependent manner (n = 3-12 mice per group, from two to three independent experiments). Data are mean + SEM. p-values were calculated using one-way ANOVA with Bonferroni correction, *p < .05, **p < .001, ***p < .0001
pathologic NV and promoting physiologic revascularization. Protection of retinal neurons has also been shown to promote revascularization in the OIR model (Wei et al., 2015) . Our ISH data shows that miR-30a is widely expressed across the retina, suggesting it may also be expressed by retinal neurons. Of note, miR-30a inhibition in cortical neurons has been shown to protect against ischemia-induced cell death (Wang, Zhang, et al., 2015) . Thus, it is possible that in addition to curbing pathological angiogenesis and promoting revascularization through its effects on endothelial and microglial cells, miR-30a inhibition may also result in protection of retinal neurons from ischemic damage. 2016). Thus, the prevailing view is that CCL2 plays a major role in many brain and retinal diseases. It was surprising to us that elevated CCL2 was associated with reduced angiogenesis and increased tissue repair. However, there is some evidence that, CCL2 may also be protective. Ischemic injury in the brain can be prevented by ischemic preconditioning. In this paradigm, a brief mild ischemic episode is triggered and this initiates a cascade of molecular and cellular events that protect the brain from damage when subsequent severe ischemic events are triggered. CCL2 has been shown to be a major component of this protective effect and CCL2 depletion completely ablates it (Stowe et al., 2012; . High levels of CCL2 have also been detected in diabetic wounds, and it has been thought that CCL2 would prevent wound repair. However, recent studies showed that instead, CCL2 is required for appropriate tissue repair following epidermal wounding (Wood et al., 2014) and ischemic kidney injury (Stroo et al., 2015) . Accordingly, one study showed that in a rat model of cerebral hemorrhage, while CCL2 ablation reduced initial injury size, it significantly slowed recovery (Yao & Tsirka, 2012) .
In the retina, some studies have shown that CCL2 depletion aggravates laser-induced choroidal NV and accelerates neurodegeneration (Luhmann et al., 2009; Yu et al., 2015) . These studies suggest that CCL2, consistent with our results, is a key player in protection following ischemia and in mediating tissue repair. Furthermore, we show that CCL2 can promote microglia phagocytic function, a potential mechanism by which this chemokine may promote tissue repair. and so it has been hypothesized that CCL2 may contribute to the pathology in these conditions. In light of our results, it is interesting to FIGURE 6 miR-30a inhibition and CCL2 expression promote microglia phagocytic function. (a) Intravitreal injection of miR-30a inhibitor resulted in upregulation of several mRNAs involved in phagocytic responses. n = 3, data is representative of two independent experiments (b, c) inhibition of miR-30a resulted in increased phagocytic function of microglia cells in vivo, as seen by increased uptake of fluorescent beads (n = 6 mice per group, from two independent experiments). Data are mean + SEM. p-value was calculated using two-tailed Student's t-test, ***p < .0001. (d, e) Injection of recombinant CCL2 led to an increase in phagocytic function in a dose dependent manner (n = 9 mice per group, from three independent experiments) data are mean + SEM. p-values were calculated using a one-way ANOVA with Bonferroni multiple correction, *p < .05, **p < .001, ***p < .0001
FIGURE 7 miR-30a are increased in the vitreous of patients with proliferative diabetic retinopathy. miR-30a levels in the vitreous humor of patients were measured by qPCR (n = 6-23 per group). Data are mean + SEM. p-values were calculated using one-way ANOVA with Bonferroni correction, *p = .04, ***p < .0001
speculate that the high levels of CCL2 may reflect a failed attempt of the retina to "heal itself." While this is difficult to test in humans, a recent clinical trial using an anti-CCL2 antibody for idiopathic lung fibrosis, an abnormal tissue repair response, seems to support this idea (Raghu et al., 2015) . Elevated levels of CCL2 have been detected in idiopathic lung fibrosis, which led to the use of the anti-CCL2 antibody Carlumab in clinical trials. Results from a phase II clinical trial showed that, unexpectedly, not only did anti-CCL2 therapy not improve the condition, but all treated patients had faster disease progression when compared to placebo control and over 50% of the patients treated with the highest dose of anti-CCL2 suffered severe side effects (Raghu et al., 2015) . These results caution against the use of anti-CCL2 antibodies to treat ocular disease, which is now being considered (Das, 2016) .
Vitreous can be readily obtained when patients undergo ocular surgical procedures. Analysis of vitreous samples from patients affected with PDR showed that miR-30a levels are elevated in PDR, suggesting miR-30a may be involved in the pathogenesis of PDR. Of note, while miR-30a levels are elevated in the vitreous of PDR patients, the levels of miR-30a dramatically drop at p17, the peak of the proliferative phase in OIR. We believe this disparity in our data may be explained by the different tissue responses to ischemic injury in humans and mice. Unlike PDR in humans, the mouse retina can repair itself following ischemic injury in the OIR model. While histologically the proliferative phase peaks at p17, this is also when tissue repair responses begin (Connor et al., 2009 ). Thus, we believe the drop in miR-30a levels at p17 may act as a signal to trigger tissue repair responses. In contrast, in humans with PDR, miR-30a levels remain elevated, potentially hindering the onset of repair responses.
Although more work is necessary to determine the role of miR-30a in ischemic pathologies, its elevated levels suggest that miR-30a may be involved in the pathology of PDR. As miR-30a targets several mRNAs, it is possible that miR-30a inhibition would be an effective therapy against ischemic neovascular disorders, by targeting endothelial Fas and microglial behavior.
In summary, the results described here identify miR-30a as an important regulator of angiogenesis in retinal ischemia. While more studies are warranted to fully understand the scope of miR-30a's action, we have been able to demonstrate that Fas and CCL2 are two important mediators of the antiangiogenic and protective effects of miR-30a. Given the broad expression of miR-30a and CCL2 in ischemic disease, these results may have implications for other diseases of the CNS.
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